recommendation based on very-low-quality evidence; may consider starting an OSM (specifically apremilast) if the patient has recurrent infections. Strong recommendation supported by moderate-quality evidence, showing TNFi monoclonal antibody biologics are effective in IBD but indirect evidence shows a TNFi biologic soluble receptor biologic is not effective for the treatment of IBD. In adult patients with active 16. Switch to a TNFi monoclonal antibody biologic over an IL-17i biologic (PICO 59) Moderate ( 50 Strong recommendation supported by moderate-quality evidence showing monoclonal antibody TNFi biologics are effective for IBD while an IL-17i biologic is not effective for IBD. Switch to a TNFi biologic monoclonal antibody biologic over an IL-12/23i biologic (PICO 61) Very low Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure,